BRCA1 and ovarian carcinoma: Still, currently there is no clear rationale regarding which PARPi to use, for which ovarian cancer patients beyond FDA endorsement of olaparib, rucaparib or niraparib when a mutation is present in BRCA1 or BRCA2 after first-line platinum-based chemotherapy or as maintenance therapy [30,42].